Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SQM006
MIFTS: 60

Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 74 20 36 29 6 15 17 71
Carcinoma, Squamous Cell 74 20 44
Epidermoid Carcinoma 12 74 20
Squamous Cell Cancer 12 54 15
Squamous Cell Carcinoma - Category 71
Malignant Squamous Cell Neoplasm 71
Squamous Cell Carcinoma of Skin 71
Malignant Squamous Cell Tumor 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 20
Neoplasms, Squamous Cell 44
Carcinoma Squamous Cell 54
Squamous Carcinoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1749
KEGG 36 H00040
NCIt 50 C2929
SNOMED-CT 67 154605007
UMLS 71 C0007137 C0553723 C0751688 more
Sources

Summaries for Squamous Cell Carcinoma

About this section
KEGG : 36 Non-melanoma skin cancer, i.e. basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most frequent tumors and their number is still increasing world- wide. Approximately 200000 cases of SCC develop per year, causing about 2000 deaths. Unlike BCCs, which have no known precursor lesions, SCCs can emerge from actinic keratoses. As with BCC, risk for development of SCC is strongly influenced by the nature and dose of UV radiation and genetic backgrounds that regulate that interaction. Mutations in TP53 have been described in actinic keratoses, in situ SCC, and invasive SCC with UV signature lesions common, and a reported mutation rate as high as 45%. As with TP53, UV-induced mutations in HRAS and KRAS have also been characterized in both actinic keratoses and SCC. The reported frequency of RAS mutations in SCCs ranges from approximately 10% to almost 50%. Several recent studies have also reported mutations of p16 in up to 24% of SCCs. In addition to UV, a pathogenic role for human papillomavirus (HPV) in the development of SCC has also been proposed.

MalaCards based summary : Squamous Cell Carcinoma, also known as carcinoma, squamous cell, is related to squamous cell carcinoma, head and neck and laryngeal squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma is DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs mometasone furoate and Titanium dioxide have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and skin.

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

GARD : 20 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure. With appropriate treatment, it is usually curable.

Wikipedia : 74 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Sources

Related Diseases for Squamous Cell Carcinoma

About this section

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1809)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 33.5 SPRY4-IT1 MIR205 HOTAIR H19 C5orf66-AS1
2 laryngeal squamous cell carcinoma 33.0 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
3 lung squamous cell carcinoma 33.0 TUG1 SOX2-OT DDR2 CCAT2
4 esophagus squamous cell carcinoma 33.0 TUG1 TINCR HOTAIR
5 esophageal cancer 32.9 UCA1 PCAT1 MIR205 MALAT1 HOTAIR H19
6 oral squamous cell carcinoma 32.9 UCA1 TUG1 NEAT1 MIR205 MALAT1 HOTAIR
7 nasopharyngeal carcinoma 32.5 NEAT1 MALAT1 HOTAIR H19 FOXCUT CDKN2B-AS1
8 lung cancer susceptibility 3 32.0 TUG1 MIR205 MALAT1 HOTAIR H19
9 bladder cancer 31.5 UCA1 TUG1 TINCR SPRY4-IT1 PCAT1 MIR205
10 thyroid carcinoma 31.4 UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
11 small cell cancer of the lung 31.4 TUG1 MALAT1 HOTAIR CCAT2
12 thyroid cancer, nonmedullary, 1 31.4 NEAT1 MALAT1 HOTAIR H19
13 melanoma 31.3 UCA1 SPRY4-IT1 SOX2-OT MIR205 MALAT1 HOTAIR
14 gastric adenocarcinoma 31.3 NEAT1 HOTAIR H19
15 lung cancer 31.3 UCA1 TUG1 TINCR SPRY4-IT1 SOX2-OT RIOX2
16 prostate cancer 31.2 UCA1 TUG1 SPRY4-IT1 PCAT1 NEAT1 MIR205
17 gastric cardia adenocarcinoma 31.2 HOTAIR H19 C5orf66-AS1
18 retinitis pigmentosa 11 31.2 UCA1 TUG1 NEAT1 HOTAIR
19 cervical cancer 31.2 UCA1 TUG1 SPRY4-IT1 PCAT1 NEAT1 MIR205
20 gallbladder cancer 31.1 UCA1 TUG1 MALAT1 HOTAIR H19 CDKN2B-AS1
21 glioblastoma 31.0 TUG1 PCAT1 MALAT1 HOTAIR H19
22 leukemia, acute myeloid 30.9 UCA1 TUG1 MALAT1 HOTAIR CDKN2B-AS1
23 renal cell carcinoma, nonpapillary 30.9 UCA1 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
24 myeloma, multiple 30.9 UCA1 TUG1 PCAT1 MALAT1 HOTAIR H19
25 bladder urothelial carcinoma 30.8 TUG1 MALAT1 HOTAIR
26 pancreatic ductal adenocarcinoma 30.7 UCA1 MIR205 MALAT1 HOTAIR H19
27 kidney cancer 30.4 MALAT1 HOTAIR H19
28 pancreatic cancer 30.3 UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
29 ovarian epithelial cancer 30.3 MALAT1 HOTAIR H19 CCAT2
30 osteogenic sarcoma 30.3 UCA1 TUG1 SOX2-OT PCAT1 NEAT1 MALAT1
31 pituitary adenoma 30.2 MALAT1 HOTAIR H19 CCAT2
32 cholangiocarcinoma 30.2 UCA1 TUG1 SPRY4-IT1 SOX2-OT PCAT1 NEAT1
33 prostatic adenoma 30.2 UCA1 CDKN2B-AS1
34 pre-eclampsia 30.2 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
35 glioma 30.2 UCA1 SPRY4-IT1 NEAT1 MALAT1 HOTAIR H19
36 high grade glioma 29.9 TUG1 SPRY4-IT1 NEAT1 MALAT1 HOTAIR H19
37 ovarian cancer 29.8 UCA1 TUG1 SPRY4-IT1 SOX2-OT NEAT1 MIR205
38 hepatocellular carcinoma 29.8 UCA1 TUG1 SPRY4-IT1 SOX2-OT RIOX2 PCAT1
39 gastric cancer 29.7 UCA1 TUG1 TINCR SPRY4-IT1 SOX2-OT RIOX2
40 breast cancer 29.3 UCA1 TUG1 SPRY4-IT1 SOX2-OT NEAT1 MIR205
41 colorectal cancer 28.7 UCA1 TUG1 TINCR SPRY4-IT1 SOX2-OT PCAT1
42 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 11.8
43 tongue squamous cell carcinoma 11.8
44 cervical squamous cell carcinoma 11.8
45 basaloid squamous cell carcinoma 11.8
46 gastric squamous cell carcinoma 11.7
47 conjunctival squamous cell carcinoma 11.7
48 rectum squamous cell carcinoma 11.7
49 vulva squamous cell carcinoma 11.7
50 keratinizing squamous cell carcinoma 11.7

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Squamous Cell Carcinoma

About this section
Sources

Drugs & Therapeutics for Squamous Cell Carcinoma

About this section

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Titanium dioxide Approved Phase 4 13463-67-7
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6
Cevimeline Approved Phase 4 107233-08-9 83898 25137844
7
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
8
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
9 Anti-Allergic Agents Phase 4
10 Triamcinolone hexacetonide Phase 4
11 triamcinolone acetonide Phase 4
12 Triamcinolone diacetate Phase 4
13 Tin Fluorides Phase 4
14 Neurotransmitter Agents Phase 4
15 Adjuvants, Immunologic Phase 4
16 Cholinergic Agents Phase 4
17 Antirheumatic Agents Phase 4
18 retinol Phase 4
19 Retinol palmitate Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Analgesics Phase 4
24 Fibrin Tissue Adhesive Phase 4
25 Muscarinic Agonists Phase 4
26 Alkylating Agents Phase 4
27 Antibiotics, Antitubercular Phase 4
28 Anti-Bacterial Agents Phase 4
29 Mitomycins Phase 4
30
Racepinephrine Approved Phase 3 329-65-7 838
31
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
32
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
33
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
34
Trioxsalen Approved Phase 3 3902-71-4 5585
35
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
36
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
37
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
38
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
39
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
40
Tocopherol Approved, Investigational Phase 3 1406-66-2
41
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
42
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
43
Dapsone Approved, Investigational Phase 3 80-08-0 2955
44
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
45
leucovorin Approved Phase 3 58-05-9 6006
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Lenvatinib Approved, Investigational Phase 3 417716-92-8
49
Ifosfamide Approved Phase 3 3778-73-2 3690
50
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 1991)
# Name Status NCT ID Phase Drugs
1 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Unknown status NCT03725423 Phase 4 Apatinib
2 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study Unknown status NCT02513342 Phase 4 Docetaxel;Cisplatin
3 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
4 A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
5 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
6 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
7 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
8 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
9 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
10 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
11 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
12 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
13 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
14 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Recruiting NCT04132102 Phase 4 Afatinib
15 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
16 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). Recruiting NCT04489888 Phase 4 Pembrolizumab;Carboplatin;Paclitaxel
17 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
18 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
19 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
20 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase â…¢ Study Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
21 Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma Unknown status NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
22 A Multicenter Phase â…¢ Trial of Cisplatin Plus Raltitrexed or 5-fluorouracil in Concurrence With Intensity-modulated Radiotherapy (IMRT) for the Treatment of Locoregionally Advanced Head and Neck Squamous Cell Cancer Unknown status NCT02485548 Phase 3 Raltitrexed;5-fluorouracil;Cisplatin
23 Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial. Unknown status NCT01496521 Phase 3 Aspirin
24 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Unknown status NCT02661152 Phase 3 Nimorazole
25 An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
26 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Unknown status NCT02603159 Phase 3 Capecitabine(Aibin)
27 A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
28 Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma Unknown status NCT01874171 Phase 3 Cisplatin;Cetuximab
29 Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer Unknown status NCT02607540 Phase 3
30 Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase â…¢ Trial Unknown status NCT01398449 Phase 3
31 Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial Unknown status NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
32 An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas Unknown status NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
33 A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma Unknown status NCT02570893 Phase 3 Paclitaxel and carboplatin
34 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
35 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
36 A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
37 Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Unknown status NCT02375997 Phase 3
38 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
39 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
40 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
41 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
42 Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study Unknown status NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
43 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
44 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
45 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
46 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
47 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
48 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
49 Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer Unknown status NCT03656393 Phase 3 Gefitinib;Vinorelbine;Carboplatin
50 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Afatinib
afatinib dimaleate
pembrolizumab

Cochrane evidence based reviews: carcinoma, squamous cell

Sources

Genetic Tests for Squamous Cell Carcinoma

About this section

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 29
Sources

Anatomical Context for Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Squamous Cell Carcinoma:

40
Tongue, Lymph Node, Skin, Cervix, Lung, Endothelial, Thyroid
Sources

Publications for Squamous Cell Carcinoma

About this section

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 37470)
# Title Authors PMID Year
1
Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. 61 54
20036791 2010
2
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma. 54 61
20034753 2010
3
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. 54 61
20470671 2010
4
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. 61 54
20360610 2010
5
Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway. 61 54
20371243 2010
6
Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? 54 61
20363547 2010
7
Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma. 54 61
20451846 2010
8
Tumor-related protein, the squamous cell carcinoma antigen binds to the intracellular protein carbonyl reductase. 54 61
20428762 2010
9
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. 54 61
20415599 2010
10
Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. 54 61
19615795 2010
11
Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus. 61 54
20527047 2010
12
Downregulation of N-cadherin expression inhibits invasiveness, arrests cell cycle and induces cell apoptosis in esophageal squamous cell carcinoma. 54 61
20014942 2010
13
Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. 61 54
20014947 2010
14
TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. 61 54
20308003 2010
15
Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population. 61 54
20416519 2010
16
Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. 61 54
20207580 2010
17
Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. 61 54
20188165 2010
18
Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. 54 61
20393745 2010
19
Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. 61 54
20372803 2010
20
Decreased GRP78 protein expression is a potential prognostic marker of oral squamous cell carcinoma in Taiwan. 61 54
20497865 2010
21
Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. 54 61
20429940 2010
22
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. 61 54
19780905 2010
23
Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. 61 54
20136698 2010
24
Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma. 54 61
20186700 2010
25
Cobalt chloride stimulates phosphoinositide 3-kinase/Akt signaling through the epidermal growth factor receptor in oral squamous cell carcinoma. 61 54
20506627 2010
26
GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. 61 54
20428049 2010
27
Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. 61 54
20040021 2010
28
VEGF-C contributes to head and neck squamous cell carcinoma growth and motility. 61 54
20227330 2010
29
A novel homozygous keratin 14 mutation in a patient with autosomal recessive epidermolysis bullosa simplex and squamous cell carcinoma of the tongue. 61 54
20096008 2010
30
p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. 61 54
20388212 2010
31
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. 61 54
20204279 2010
32
HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. 61 54
20204276 2010
33
Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. 61 54
20389301 2010
34
Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma. 54 61
20150431 2010
35
mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. 54 61
19853373 2010
36
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. 54 61
20101235 2010
37
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. 61 54
20215534 2010
38
Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. 54 61
20460738 2010
39
The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus. 61 54
20012971 2010
40
Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. 54 61
19823871 2010
41
Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity. 61 54
19576666 2010
42
Effects of bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell carcinoma. 61 54
20074910 2010
43
The clinicopathological significance of the expression of Granzyme B in oral squamous cell carcinoma. 61 54
20060355 2010
44
Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. 61 54
20060356 2010
45
FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. 54 61
20127014 2010
46
Expression and clinical significance of Ezrin and E-cadherin in esophageal squamous cell carcinoma. 54 61
20193117 2010
47
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. 54 61
19662650 2010
48
The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma. 61 54
19954817 2010
49
Expression and significance of tumor drug resistance related proteins and beta-catenin in esophageal squamous cell carcinoma. 54 61
20193114 2010
50
Lack of Fas-pathway gene mutations in primary resected esophageal squamous cell carcinoma. 61 54
20438666 2010
Sources

Variations for Squamous Cell Carcinoma

About this section

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DDR2 NM_006182.4(DDR2):c.2304T>A (p.Ser768Arg) SNV Pathogenic 375878 rs267598140 1:162748390-162748390 1:162778600-162778600
2 EGFR-AS1 NM_005228.5(EGFR):c.2428G>A (p.Gly810Ser) SNV Likely pathogenic 376278 rs121913230 7:55249130-55249130 7:55181437-55181437
3 EGFR-AS1 NM_005228.5(EGFR):c.2429G>A (p.Gly810Asp) SNV Likely pathogenic 376279 rs121913431 7:55249131-55249131 7:55181438-55181438

Cosmic variations for Squamous Cell Carcinoma:

9 (show top 50) (show all 4245)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM144087146 TP53 skin,arm,carcinoma,basal cell carcinoma c.245C>T p.S82F 17:7674241-7674241 20
2 COSM106059757 TP53 skin,hand,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 20
3 COSM144653327 TP53 skin,face,carcinoma,basal cell carcinoma c.*131C>T p.? 17:7670685-7670685 20
4 COSM143944147 TP53 skin,arm,carcinoma,squamous cell carcinoma c.265C>T p.R89W 17:7674221-7674221 20
5 COSM112354551 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 20
6 COSM112254631 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 20
7 COSM143371865 TP53 skin,face,carcinoma,basal cell carcinoma c.469C>T p.R157* 17:7674945-7674945 20
8 COSM111759858 TP53 skin,hand,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 20
9 COSM93183824 TP53 skin,face,carcinoma,basal cell carcinoma c.680C>T p.S227F 17:7674283-7674283 20
10 COSM144129644 TP53 skin,ear,carcinoma,squamous cell carcinoma c.225C>A p.Y75* 17:7674261-7674261 20
11 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 20
12 COSM122483449 TP53 skin,ear,carcinoma,squamous cell carcinoma c.592C>T p.L198F 17:7673540-7673540 20
13 COSM144311040 TP53 skin,ear,carcinoma,squamous cell carcinoma c.707G>T p.C236F 17:7673796-7673796 20
14 COSM121875437 TP53 skin,face,carcinoma,squamous cell carcinoma c.178C>T p.Q60* 17:7674957-7674957 20
15 COSM143388508 TP53 skin,face,carcinoma,squamous cell carcinoma c.629G>C p.R210T 17:7674217-7674217 20
16 COSM111758868 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
17 COSM142570304 TP53 skin,face,carcinoma,basal cell carcinoma c.715C>T p.P239S 17:7673788-7673788 20
18 COSM142560384 TP53 skin,face,carcinoma,squamous cell carcinoma c.616G>T p.G206C 17:7674230-7674230 20
19 COSM142742951 TP53 skin,face,carcinoma,basal cell carcinoma c.315G>A p.Q105= 17:7675180-7675180 20
20 COSM105639284 TP53 skin,face,carcinoma,basal cell carcinoma c.712T>A p.C238S 17:7674251-7674251 20
21 COSM112253879 TP53 skin,face,carcinoma,basal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
22 COSM121878773 TP53 skin,face,carcinoma,basal cell carcinoma c.241C>T p.R81* 17:7674894-7674894 20
23 COSM111776406 TP53 skin,face,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 20
24 COSM142837551 TP53 skin,face,carcinoma,basal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
25 COSM122742188 TP53 skin,face,carcinoma,basal cell carcinoma c.58C>T p.P20S 17:7675158-7675158 20
26 COSM122735020 TP53 skin,face,carcinoma,basal cell carcinoma c.190C>T p.R64* 17:7674945-7674945 20
27 COSM144869526 TP53 skin,ear,carcinoma,squamous cell carcinoma c.871C>T p.L291F 17:7673540-7673540 20
28 COSM145161899 TP53 skin,hand,carcinoma,squamous cell carcinoma c.833A>G p.Q278R 17:7673578-7673578 20
29 COSM144028845 TP53 skin,face,carcinoma,basal cell carcinoma c.679T>A p.C227S 17:7674251-7674251 20
30 COSM144021997 TP53 skin,face,carcinoma,squamous cell carcinoma c.421C>T p.P141S 17:7675158-7675158 20
31 COSM144015364 TP53 skin,face,carcinoma,basal cell carcinoma c.604C>T p.R202* 17:7674894-7674894 20
32 COSM121877621 TP53 skin,face,carcinoma,basal cell carcinoma c.190C>T p.R64* 17:7674945-7674945 20
33 COSM93201188 TP53 skin,face,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 20
34 COSM106063640 TP53 skin,ear,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 20
35 COSM144658487 TP53 skin,face,carcinoma,squamous cell carcinoma c.143C>A p.P48Q 17:7676109-7676109 20
36 COSM142639459 TP53 skin,face,carcinoma,squamous cell carcinoma c.597T>A p.C199* 17:7674249-7674249 20
37 COSM105620390 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 20
38 COSM105847654 TP53 skin,ear,carcinoma,squamous cell carcinoma c.782+641C>T p.? 17:7673540-7673540 20
39 COSM144014436 TP53 skin,face,carcinoma,basal cell carcinoma c.553C>T p.R185* 17:7674945-7674945 20
40 COSM112254266 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 20
41 COSM112253194 TP53 skin,face,carcinoma,basal cell carcinoma c.833C>G p.P278R 17:7673787-7673787 20
42 COSM112283184 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 20
43 COSM112263720 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 20
44 COSM122272676 TP53 skin,face,carcinoma,basal cell carcinoma c.190C>T p.R64* 17:7674945-7674945 20
45 COSM93239210 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 20
46 COSM145019215 TP53 skin,hand,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7673764-7673764 20
47 COSM105620642 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
48 COSM144013959 TP53 skin,face,carcinoma,basal cell carcinoma c.502C>T p.H168Y 17:7675077-7675077 20
49 COSM143949062 TP53 skin,face,carcinoma,squamous cell carcinoma c.263A>C p.N88T 17:7674223-7674223 20
50 COSM111813264 TP53 skin,ear,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 20

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number CADM1 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain APOLD1 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain Squamous cell cancer
18 66579 12 3100000 5300000 Gain Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1P41 Squamous cell cancer
25 95699 15 79500000 83000000 Loss Squamous cell cancer
26 95701 15 79500000 83000000 Loss Squamous cell cancer
27 95703 15 79500000 83000000 Loss Squamous cell cancer
28 95705 15 79500000 83000000 Loss Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain ODF3L2 Squamous cell cancer
39 124168 19 1 6900000 Gain TPGS1 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain MECOM Squamous cell cancer
50 171549 3 169200000 172500000 Gain Squamous cell cancer
Sources

Expression for Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Squamous Cell Carcinoma.
Sources

Pathways for Squamous Cell Carcinoma

About this section

Pathways related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
LncRNA-mediated mechanisms of therapeutic resistance 1
9.7 UCA1 HOTAIR
Sources

GO Terms for Squamous Cell Carcinoma

About this section
Sources

Sources for Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....